Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Fineline Cube Apr 27, 2026
Company Drug

Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100

Fineline Cube Sep 21, 2024

Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval...

Company Drug

Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study

Fineline Cube Sep 20, 2024

China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...

Company Drug

Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan

Fineline Cube Sep 20, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA

Fineline Cube Sep 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization

Fineline Cube Sep 20, 2024

JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute...

Company Deals

Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round

Fineline Cube Sep 20, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D...

Company

CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President

Fineline Cube Sep 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Sinopharm Holding Appoints New Chairman and President Following Leadership Changes

Fineline Cube Sep 20, 2024

Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of...

Medical Device Policy / Regulatory

China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices

Fineline Cube Sep 20, 2024

The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment...

Company

Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership

Fineline Cube Sep 20, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...

Company Drug

Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment

Fineline Cube Sep 19, 2024

Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine...

Company Deals

Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream

Fineline Cube Sep 19, 2024

US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a...

Company Drug

MSD’s Keytruda Secures FDA Approval for First-Line Mesothelioma Treatment in Combination with Chemotherapy

Fineline Cube Sep 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that the US Food and...

Company Drug

AstraZeneca’s Fasenra Secures FDA Nod for EGPA Treatment, Strengthening Rare Disease Portfolio

Fineline Cube Sep 19, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced that the US Food and...

Company Deals

Fidson Healthcare Partners with Chinese Entities to Establish Drug Plant in Nigeria

Fineline Cube Sep 19, 2024

Nigeria-based pharmaceutical manufacturer Fidson Healthcare Plc has entered into a strategic partnership with Jiansu Aidea...

Company Deals

MGI Tech Joins Forces with Dasa to Enhance Precision Medicine in Brazil Through Advanced Genomic Sequencing

Fineline Cube Sep 19, 2024

MGI Tech Co., Ltd, a leading gene sequencing company based in China, has announced a...

Company Drug

AstraZeneca’s Tagrisso Achieves Milestones in Phase III LAURA Study for EGFR-mutated NSCLC at ESMO 2024

Fineline Cube Sep 19, 2024

Global pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN, LON: AZN) has reported updated results from the...

Company Drug

Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy

Fineline Cube Sep 19, 2024

China-based biotech company Keymed Biosciences Inc. (HKG: 2162) has reached a significant milestone with its...

Company Drug

Adagene’s ADG126 Shows Promising Results in Phase Ib/II Study for MSS CRC at ESMO 2024

Fineline Cube Sep 19, 2024

Adagene Inc. (NASDAQ: ADAG), a biopharmaceutical company dedicated to the discovery and development of innovative...

Company Drug

Transcenta’s Osemitamab Combo Therapy Shows Promising Results in G/GEJ Cancer Treatment at ESMO 2024

Fineline Cube Sep 19, 2024

Transcenta Holdings Ltd (HKG: 6628), a leading biopharmaceutical company, has announced updated positive results from...

Posts pagination

1 … 286 287 288 … 657

Recent updates

  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
  • AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Company Drug

AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.